ArticleThe Journal of antimicrobial chemotherapy2016
Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa.
Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Evolution of Candidaemia and azole resistance in Italy: A multicentre retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Incidence of azole resistance among clinical isolates ofNew microbes and new infections · 2026Article
- Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.Emerging infectious diseases · 2026Article
- Identification ofMicrobiology spectrum · 2026Article
- Detection of Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Bacterial and fungal pathogens causing neonatal sepsis and associated antimicrobial resistance in South African neonatal units-a systematic review.JAC-antimicrobial resistance · 2025Review
- Recent Systemic Antifungal Exposure and Nonsusceptible Candida in Hospitalized Patients, South Africa, 2012-2017.Emerging infectious diseases · 2025Article
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Epidemiology of Candidemia in Children and Neonates in Korea, 2009-2018: A Multi-Center Study.Journal of Korean medical science · 2025Article
- The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- The S862C amino acid change in CpMrr1 confers fluconazole resistance inJAC-antimicrobial resistance · 2025Article
- Pathogen aetiology and risk factors for death among neonates with bloodstream infections at lower-tier South African hospitals: a cross-sectional study.The Lancet. Microbe · 2025Article
- Antimicrobial Activity of the Peptide C14R Against Ab Initio Growing and Preformed Biofilms ofBiomolecules · 2025Article
- Rapid Identification of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2025Article
- Addressing the silent threat: managing invasiveFrontiers in pediatrics · 2025Review
- The role ofJournal of medical microbiology · 2024Article
- Standardization of polymerase chain reaction for detection of fluconazole resistance targeting Y132F mutation inCurrent medical mycology · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
objectivesTo compare Candida species distribution and antifungal susceptibility at South African public- and private-sector hospitals.
methodsFrom February 2009 through to August 2010, laboratory-based surveillance for candidaemia was undertaken at 11 public-sector hospitals and >85 private-sector hospitals across South Africa. A case was defined as a patient of any age admitted to a sentinel hospital with isolation of Candida species from blood culture. Viable isolates were identified and tested for antifungal susceptibility at a reference laboratory. Demographic and limited clinical data were abstracted from laboratory records.
resultsIn total, 2172 cases of candidaemia were detected. Among patients with available data, almost two-thirds were critically ill (719/1138, 63%). On multivariable analysis, neonates [adjusted OR (aOR), 2.2; 95% CI, 1.5-3.1; P < 0.001] and patients diagnosed in Gauteng province (aOR, 1.9; 95% CI, 1.3-2.7; P < 0.001) or in the private sector (aOR, 1.9; 95% CI, 1.2-3.2; P = 0.008) were significantly more likely to be infected with Candida parapsilosis than any other Candida species. Of 531 C. parapsilosis isolates, only 199 (37%) were susceptible to fluconazole and voriconazole; 44% (123/282) of fluconazole-resistant isolates were voriconazole cross-resistant. Factors associated with fluconazole non-susceptible C. parapsilosis infection on multivariable analysis included diagnosis in Gauteng province (aOR, 4.2; 95% CI, 2.7-6.7; P < 0.001), an ICU (aOR, 2.3; 95% CI, 1.5-3.6; P < 0.001) or the private sector (aOR, 2.2; 95% CI, 1.4-3.5; P < 0.001).
conclusionsThe dominance of triazole non-susceptible C. parapsilosis limits the choice of antifungal agents for management of candidaemia among critically ill neonates, children and adults in resource-limited South African hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.